Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov57610.25208/vdv576ArticlesСтатьиResearch ArticleScalp psoriasis: new potential of the topical therapyПсориаз волосистой части головы: новые возможности топической терапииBakulevA LБакулевА Л

д.м.н., профессор, профессор кафедры кожных и венерических болезней

al_ba05@mail.ruKravchenyaS SКравченяС С

к.м.н., заведующий отделением клиники кожных и венерических болезней

Saratov State Medical University named after V.I. RazumovskyГБОУ ВПО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России15042013892NO2 (2013)№2 (2013)737811032020Copyright ©; 2013, Bakulev A.L., Kravchenya S.S.Copyright ©; 2013, Бакулев А.Л., Кравченя С.С.2013Bakulev A.L., Kravchenya S.S.Бакулев А.Л., Кравченя С.С.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/576

Clobetasol propionate is a potent topical corticosteroid that is widely used for the treatment of scalp psoriasis today. The review provides data obtained as a result of numerous clinical studies meeting the requirements of evidence-based medicine concerning the efficacy and safety of a new drug form — Clobetasol Propionate 0.05% Shampoo. Its short-term administration arrests exacerbations of dermatosis while a long-term proactive therapy prevents the development of new psoriatic eruptions on the sculp. Such issues as cosmetic acceptability and compliance of Clobetasol Propionate Shampoo for patients suffering from the scalp psoriasis are discussed.

Клобетазола пропионат — мощный топический кортикостероид, широко применяемый в настоящее время для лечения псориаза волосистой части головы. В обзоре приводятся данные многочисленных клинических исследований, отвечающих принципам доказательной медицины, по эффективности и безопасности применения новой лекарственной формы — шампуня клобетазола пропионата 0,05%. Его краткосрочное применение позволяет купировать обострение дерматоза, а долгосрочная проактивная терапия — предотвращать появление новых псориатических высыпаний на коже волосистой части головы. Обсуждаются вопросы высокой косметической приемлемости и комплаентности шампуня клобетазола пропионата у больных с псориазом волосистой части головы.

psoriasisscalpclobetasol propionateshampooefficacysafetycomplianceпсориазволосистая часть головыклобетазола пропионатшампуньэффективностьбезопасностькомплаентностьLebwohl M. Psoriasis. Lancet 2003; 361: 1197—1204.Wolff K., Goldsmith L., Katz S. i dr. Fitzpatrick’s Dermatology in General Medicine. Pod red. A.A. Kubanovoy. M.: izd-vo Panfilova; BINOM 2012; 1: 180—206.Lench N., Iles M.M., Mackay I. et al. Single-point haplotype scores telomeric to human leukocyte antigen-C give a high susceptibility major histocompatability complex haplotype for psoriasis in a caucasian population. J Invest Dermatol 2005; 124 (3): 545—552.Gelfand J.M., Feldman S.R., Stern R.S. et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51 (5): 704—708.Schlaak J.F., Buslau M., Jochum W. et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102 (2): 145—149.Gudjonsson J.E., Johnston A., Sigmundsdottir H., Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135(1): 1—8.Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. JEADV 2012 (2): 3—11.Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009; 361: 496—509.Van de Kerkhof P.C., de Hoop D., de Korte J., Kuipers M.V. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197: 326—334.Dawber R. Diseases involving the scalp. In: Rook A., Dawber R., editors. Diseases of the hair and scalp. Oxford: Blackwell Scientific Publications 1991; 506— 509.Pathirana D., Ormerod A.D., Saiag P. et al. European S3 Guidelines on the systemic treatment of psoriasis vulgaris. JEADV 2009: 23 (2); 5—69.Munro D.D. Disease of the skin. Treatment of scalp disorder. Br Med J 1974; 1 (901): 236—238.Matsunaga J., Maibach H.I. Scalp and hair. In: Roenigk H.H., Jr. Maibach H.I. eds. Psoriasis Marcel Dekker, New York, 1985: 95—100.Weiss S.C., Kimball A.B., Liewehr D.J. et al. Quantifying the harmful effect of psoriasis on health related quality of life. J Am Acad Dermatol 2002; 47 (4): 512—518.Jarratt M., Breneman D., Gottlieb A.B. et al. Clobetasol propionate shampoo 0.05%: A new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3 (4): 367—373.Gottlieb A.B., Ford R.O., Spellman M.C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185—192.Bergstrom K.G., Arambula K., Kimball A.B. Medication formulation affects quality of life: a randomized singleblind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72: 407—411.Mazzotta A., Esposito M., Carboni I. et al. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat 2007; 18: 84—87.Reygagne P., Mrowietz U., Decroix J. et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: 31—36.Griffiths C.E., Finlay A.Y., Fleming C.J. et al. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006; 17: 90—95.Housman T.S., Keil K.A., Mellen B.G. et al. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 2003; 49: 79—82.Richards R.N. Clinical experience with 0.05% clobetasol propionate creams (Correspondence). J Am Acad Dermatol 1985; 12: 891—892.Olsen E.A., Cornell R.C. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986; 15: 246—255.Langner A., Wolska H., Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983; 32: 290—296.Lassus A. Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17, 21-dipropionate: a double-blind comparison. Curr Med Res Opin 1976; 4: 365—367.Hovding G. Treatment of psoriasis of the scalp with betamethasone 17, 21- dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981; 3: 61—66.Katz H.I., Lindholm J.S., Weiss J.S. et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17: 390—401.Feldman S.R. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin Dermatol 2006; 24 (3): 229—230.Poulin Y., Papp K., Bissonnette R. et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85: 43—50.Housman T.S., Mellen B.G., Rapp S.R. et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70: 327—332.Tan J., Thomas R., Wang B., et al. Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis. Cutis. 2009; 83(3): 157—164.Chen S.C., Yeung J., Chren M.M. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002; 138: 803—807.